Axon Enterprise, Inc (NASDAQ:AXON) Receives Consensus Rating of “Moderate Buy” from Analysts

Axon Enterprise, Inc (NASDAQ:AXON) has been given a consensus rating of “Moderate Buy” by the eighteen brokerages that are covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and fifteen have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $805.7143.

A number of research firms recently weighed in on AXON. William Blair reaffirmed an “outperform” rating on shares of Axon Enterprise in a report on Tuesday. UBS Group dropped their price objective on Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. Northcoast Research raised shares of Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 target price for the company in a research note on Tuesday, January 6th. The Goldman Sachs Group decreased their price target on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Finally, Royal Bank Of Canada started coverage on shares of Axon Enterprise in a research note on Monday, November 17th. They issued an “outperform” rating and a $860.00 price objective for the company.

Insider Buying and Selling at Axon Enterprise

In related news, President Joshua Isner sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $552.60, for a total transaction of $11,052,000.00. Following the transaction, the president directly owned 249,502 shares of the company’s stock, valued at approximately $137,874,805.20. The trade was a 7.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Jennifer H. Mak sold 1,134 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $600.00, for a total transaction of $680,400.00. Following the transaction, the chief accounting officer owned 13,740 shares in the company, valued at approximately $8,244,000. This represents a 7.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 60,540 shares of company stock valued at $34,684,738 in the last 90 days. Corporate insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Axon Enterprise

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in shares of Axon Enterprise by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock valued at $5,319,928,000 after acquiring an additional 53,060 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Axon Enterprise by 5.9% in the 2nd quarter. Geode Capital Management LLC now owns 2,072,186 shares of the biotechnology company’s stock valued at $1,713,332,000 after purchasing an additional 115,349 shares during the period. Baillie Gifford & Co. lifted its stake in shares of Axon Enterprise by 1,198.7% in the fourth quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock valued at $932,869,000 after buying an additional 1,516,099 shares during the period. Jennison Associates LLC lifted its position in shares of Axon Enterprise by 53.8% in the 3rd quarter. Jennison Associates LLC now owns 943,944 shares of the biotechnology company’s stock worth $677,412,000 after acquiring an additional 330,213 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its position in Axon Enterprise by 23.0% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 838,289 shares of the biotechnology company’s stock worth $476,089,000 after purchasing an additional 156,647 shares during the period. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Trading Down 1.9%

NASDAQ AXON opened at $451.29 on Wednesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.89 and a current ratio of 3.12. Axon Enterprise has a one year low of $434.62 and a one year high of $885.91. The company has a 50-day simple moving average of $575.49 and a 200-day simple moving average of $664.42. The firm has a market capitalization of $35.61 billion, a PE ratio of 142.81, a price-to-earnings-growth ratio of 13.86 and a beta of 1.48.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share for the quarter, missing the consensus estimate of $1.63 by ($0.46). The business had revenue of $710.64 million for the quarter, compared to analyst estimates of $704.83 million. Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.Axon Enterprise’s revenue was up 30.6% compared to the same quarter last year. During the same quarter last year, the company earned $1.45 EPS. On average, equities analysts forecast that Axon Enterprise will post 5.8 earnings per share for the current year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.